Teva issues 2015 business outlook short of expectations

11 December 2014
drugs_pills_tablets_big

Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) saw its shares gain 1.17% to $57.05, despite releasing a flat outlook for 2015.

The company expects net revenue in 2015 of between $19.0 and $19.4 billion. Operating income is forecast at $5.7 to $5.9 billion, with earnings per share of $5.00 to $5.30.

This falls short of analysts’ forecast for EPS of $5.06 and revenue of $20.1 billion, according to Thomson Reuters. Teva is forecast to earn $5.06 a share in 2014 on revenue of $20.3 billion, noted Reuters.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics